Management of Grapefruit-Drug Interactions AMY L
Total Page:16
File Type:pdf, Size:1020Kb
Management of Grapefruit-Drug Interactions AMY L. STUMP, PHARM.D., University of Alabama School of Medicine, Tuscaloosa, Alabama TERRI MAYO, PHARM.D., DCH Regional Medical Center, Tuscaloosa, Alabama ALAN BLUM, M.D., University of Alabama School of Medicine, Tuscaloosa, Alabama Grapefruit is a healthy addition to a well-balanced diet. However, the fruit has been shown to affect the metabolism of many medications, increasing the risk of toxicity and adverse effects. Characteristics of oral medications that may interact with grapefruit include extensive metabo- lism through the intestinal cytochrome P450 3A4 system, low bioavailability, and a narrow therapeutic index. Prominent medications known to interact with grapefruit include statins, antiarrhythmic agents, immunosuppressive agents, and calcium channel blockers. There are equally effective alternatives to these drug classes that do not have the potential to interact with grapefruit. These alternative drugs may be substituted if a patient experiences or is at risk of a grapefruit-drug interaction. Patients also may choose to exclude grapefruit from their diets and consume other fruits, including other types of citrus, to avoid an interaction. (Am Fam Physician 2006;74:605-8, 611. Copyright © 2006 American Academy of Family Physicians.) Patient information: rapefruit is a citrus fruit that is MECHANISM OF INTERACTION A handout on medicine low in calories; rich in vitamin C, The characteristics of medications that inter- interactions with grape- fruit, written by the potassium, and dietary fiber; and act with grapefruit are well defined. The most authors of this article, is has been a recommended fruit of significant of these characteristics is metabo- provided on page 611. G the American Heart Association’s “Healthy lism by the intestinal cytochrome P450 3A4 Heart Campaign.”1 The authors of a study2 (CYP 3A4) system. CYP 3A4 is found in the that used grapefruit juice to mask the taste of liver and intestinal tract. Intestinal CYP 3A4 ethanol inadvertently discovered an interac- concentration can be decreased by 47 percent tion between grapefruit and the calcium chan- within four hours of grapefruit consump- nel blocker felodipine (Plendil). They observed tion.4 One study5 has shown that the interac- that patients who consumed grapefruit juice tion persists for up to 72 hours; therefore, it had felodipine plasma concentrations two to would be prudent to avoid grapefruit prod- three times higher than normal levels.2 ucts for 72 hours before taking a medication The discovery of this and other clinically with which they may interact. significant interactions may have caused Another study6 reported that consum- health care professionals to hesitate before ing 8 oz of grapefruit juice can inhibit universally recommending grapefruit as intestinal CYP 3A4 concentration for 24 to part of a healthy diet. Because grapefruit- 72 hours. Therefore, separating the times of drug interactions exist, strategies should be medication administration and grapefruit devised to manage potential interactions. consumption is not a plausible solution.5,6 A patient may choose to exclude grapefruit It is important to note that because of from his or her diet and substi- genetic polymorphism, persons have vary- tute other fruits, including any ing amounts of intestinal CYP 3A4; conse- The most significant char- other citrus.3 However, if the quently, the extent of an interaction is not acteristic that determines patient wishes to continue to predictable from patient to patient.7,8 drug interaction with consume grapefruit products, The substance or substances in grapefruit grapefruit is metabolism by an alternate medication that that inhibit intestinal CYP 3A4 have not the intestinal cytochrome does not have the potential to been identified. In addition, grapefruit may P450 3A4 system. interact with grapefruit may be decrease the intestinal transport of drugs prescribed. into the circulation.7 Because intestinal Downloaded from the American Family Physician Web site at www.aafp.org/afp. Copyright © 2006 American Academy of Family Physicians. For the private, noncommercial use of one individual user of the Web site. All other rights reserved. Contact [email protected] for copyright questions and/or permission requests. Grapefruit SORT: KEY RECOMMENDATIONS FOR PRACTICE Evidence Clinical recommendation rating References Comments Patients should discontinue grapefruit C 5, 6 The potential for a grapefruit-drug interaction consumption for 72 hours before use persists for up to 72 hours according to one of a drug that may interact with it. study.5 Potential grapefruit-drug interactions C 5, 6 Studies have shown that consuming 8 oz of cannot be avoided by separating times grapefruit juice may decrease the concentration of medication administration and of intestinal cytochrome P450 3A4 by 47 percent grapefruit consumption. for 24 to 72 hours. A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease- oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 542 or http://www.aafp.org/afpsort.xml. CYP 3A4 is affected, the interaction will only exist.10-18 Table 19,19-30 describes medication occur with oral formulations. Studies of the classes that have had documented, clini- intravenous form of drugs that are substrates cally significant interactions with grapefruit of hepatic CYP 3A4 and have the potential products, and possible alternative therapies to interact with grapefruit failed to demon- for these drugs. strate any effect on plasma concentration.4 The importance of clearly understanding Medications metabolized by intestinal possible interactions between drugs and CYP 3A4 that have a low oral bioavailability grapefruit products is becoming more evi- or a narrow therapeutic index are more likely dent. The manufacturers of cyclosporine to have clinically significant interactions (Sandimmune, Neoral) and simvastatin with grapefruit products.9 Because medica- (Zocor) have gone so far as to place warnings tions metabolized extensively by intestinal on their drugs’ package inserts.25,31,32 CYP 3A4 generally have low oral bioavail- Members of various family medicine departments develop ability, and because grapefruit inhibits this articles for “Clinical Pharmacology.” This is one in a series metabolic pathway, higher plasma concen- coordinated by Allen F. Shaughnessy, Pharm.D., and trations of these medications will result. Andrea E. Gordon, M.D., Tufts University Family Medicine Furthermore, if the medication has a narrow Residency, Malden, Mass. therapeutic index, small increases in plasma concentration may cause drastic increases in The Authors therapeutic or adverse effects.9 AMY L. STUMP, Pharm.D., is assistant clinical professor of pharmacy practice at the Auburn (Ala.) University Harrison MANAGEMENT School of Pharmacy Department of Pharmacy Practice. She also is assistant clinical professor of rural medicine in When considering how to manage grape- the University of Alabama School of Medicine Department fruit-drug interactions, a physician should of Community and Rural Medicine and the Institute for first decide if the interaction is clinically Rural Health Research, Tuscaloosa. Dr. Stump received her pharmacy degree from the University of Nebraska Medical relevant. A number of medications (e.g., Center College of Pharmacy, Omaha, and completed a angiotensin receptor blockers, buspirone primary care specialty pharmacy residency at Mission [BuSpar], estrogens, fexofenadine [Allegra], Hospitals/Mountain Area Health Education Center in itraconazole [Sporanox], silde- Asheville, N.C. nafil [Viagra], triazolam [Hal- TERRI MAYO, Pharm.D., is completing a drug information Patients should avoid cion], warfarin [Coumadin]) specialty pharmacy residency at DCH Regional Medical Center in Tuscaloosa, Ala. She received her pharmacy grapefruit products for reportedly or theoretically degree from the Auburn University Harrison School of 72 hours before taking a interact with grapefruit. How- Pharmacy. drug with which they may ever, many of these interactions ALAN BLUM, M.D., is professor and holds the Gerald interact. have not been proven clinically Leon Wallace endowed chair in family medicine at the significant, or inconsistent data University of Alabama School of Medicine. He also is 606 American Family Physician www.aafp.org/afp Volume 74, Number 4 ◆ August 15, 2006 Grapefruit TABLE 1 Grapefruit-Drug Interactions and Alternative Therapies Drugs potentially Drug class affected by grapefruit Effects of interaction Alternative treatments Antiarrhythmics Amiodarone (Cordarone), Increased plasma concentrations of Digoxin (Lanoxin), diltiazem disopyramide amiodarone may cause thyroid or (Cardizem), verapamil (Norpace), quinidine pulmonary toxicity, liver injury, QTc (Calan) prolongation, proarrhythmic disorders, Beta blockers and bradycardia.19 Increased plasma concentration of quinidine and disopyramide may be cardiotoxic causing torsades de pointes.9,20 Calcium channel Felodipine (Plendil), Increased plasma concentration may Amlodipine (Norvasc), blockers nicardipine (Cardene), lead to flushing, peripheral edema, diltiazem (Cardizem), nifedipine (Procardia), headaches, tachycardia, symptomatic verapamil (Calan) nimodipine (Nimotop), hypotension, and myocardial infarction nisoldipine (Sular) in rare cases.9 Statins Atorvastatin (Lipitor), Increased plasma concentration